<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870285</url>
  </required_header>
  <id_info>
    <org_study_id>Graz IRB 20-253 ex 08/09</org_study_id>
    <nct_id>NCT00870285</nct_id>
  </id_info>
  <brief_title>Ustekinumab Plus UVB-311nm in Psoriasis</brief_title>
  <official_title>Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ustekinumab, an IL-12/23 antibody has been approved in the E.C. and U.S.A. for the treatment
      of moderate to severe psoriasis. The aim of this study is to determine in a randomized
      half-side comparison whether additional narrowband UVB-311nm phototherapy accelerates and
      improves the clearance of skin lesions in Ustekinumab-treated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with moderate to severe psoriasis who receive standard treatment with Ustekinumab
      (45 mg at week 0, 4, and every 12 weeks) are exposed to UVB-311nm phototherapy on a
      randomized body half (left or right; head exempt) 3 x per week for six weeks and/or until
      complete response (defined as reduction in PASI to &lt; 3). PASI score, patient visual analogue
      score (VAS) for therapeutic response, and patient VAS for severity of skin lesions is
      assessed weekly; and at follow-up visits at month 3, 6, and 12. Paired Wilcoxon testing for
      differences in PASI and patient VAS scores is done; Fischer exact test is applied to
      determine differences in complete remission, PASI reduction &gt; 90%, &gt; 75% and/or 50% between
      body sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified PASI (psoriasis area and severity index)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient visual analogue (VAS) score for therapeutic effect and severity of skin lesions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>UVB 311nm radiation</intervention_name>
    <description>UVB-311nm radiation given 3 times a week to one randomized body-half</description>
    <other_name>narrow-band UVB radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Psoriasis patients who receive treatment with Ustekinumab

        Exclusion Criteria:

          -  Age below 18 years

          -  Pregnancy or lactation

          -  History of malignant melanoma

          -  History of invasive squamous cell carcinoma of the skin

          -  Dysplastic melanocytic nevus syndrome

          -  Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)

          -  Autoimmune disorders such as Lupus erythematosus or Dermatomyositis

          -  Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma
             pigmentosum, basal cell nevus syndrome, and others

          -  General poor health status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University, Department of Dermatology</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Peter Wolf, MD</investigator_full_name>
    <investigator_title>Professor of Bioimmunotherapy</investigator_title>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Biologic</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>UVB-311nm narrowband</keyword>
  <keyword>phototherapy</keyword>
  <keyword>half-side comparison</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

